JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab

BackgroundProgressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus and often fatal. Natalizumab is a highly effective therapy for multiple sclerosis (MS) but is linked to a high incidence of PML. The current metrics used to stratify MS patients at risk fo...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Qi Wu, Elizabeth A. Mills, Qin Wang, Guangmei Mao, Yang Mao-Draayer
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2025-08-01
Saila:	Frontiers in Neurology
Gaiak:	PML DMT MS cytotoxicity index OX40 immunity index natalizumab (Tysabri)
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fneur.2025.1584083/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!